While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in ...

Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...